全文获取类型
收费全文 | 201281篇 |
免费 | 18227篇 |
国内免费 | 8749篇 |
专业分类
耳鼻咽喉 | 2437篇 |
儿科学 | 4324篇 |
妇产科学 | 2141篇 |
基础医学 | 36837篇 |
口腔科学 | 7451篇 |
临床医学 | 14406篇 |
内科学 | 25664篇 |
皮肤病学 | 4587篇 |
神经病学 | 14678篇 |
特种医学 | 4391篇 |
外国民族医学 | 119篇 |
外科学 | 16996篇 |
综合类 | 31933篇 |
现状与发展 | 50篇 |
预防医学 | 5594篇 |
眼科学 | 4025篇 |
药学 | 17617篇 |
29篇 | |
中国医学 | 7173篇 |
肿瘤学 | 27805篇 |
出版年
2024年 | 151篇 |
2023年 | 2534篇 |
2022年 | 3234篇 |
2021年 | 6206篇 |
2020年 | 5955篇 |
2019年 | 5805篇 |
2018年 | 6029篇 |
2017年 | 6453篇 |
2016年 | 6822篇 |
2015年 | 7657篇 |
2014年 | 11241篇 |
2013年 | 12898篇 |
2012年 | 11106篇 |
2011年 | 12404篇 |
2010年 | 10463篇 |
2009年 | 10033篇 |
2008年 | 10645篇 |
2007年 | 10990篇 |
2006年 | 10083篇 |
2005年 | 9287篇 |
2004年 | 8379篇 |
2003年 | 7389篇 |
2002年 | 6131篇 |
2001年 | 5315篇 |
2000年 | 4506篇 |
1999年 | 3808篇 |
1998年 | 3328篇 |
1997年 | 3191篇 |
1996年 | 2748篇 |
1995年 | 2887篇 |
1994年 | 2484篇 |
1993年 | 2107篇 |
1992年 | 1749篇 |
1991年 | 1657篇 |
1990年 | 1319篇 |
1989年 | 1181篇 |
1988年 | 1114篇 |
1987年 | 889篇 |
1986年 | 950篇 |
1985年 | 1427篇 |
1984年 | 1207篇 |
1983年 | 839篇 |
1982年 | 852篇 |
1981年 | 708篇 |
1980年 | 587篇 |
1979年 | 407篇 |
1978年 | 301篇 |
1977年 | 230篇 |
1976年 | 187篇 |
1975年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
《Journal of thoracic oncology》2022,17(3):362-387
The 2021 WHO Classification of Thoracic Tumours was published earlier this year, with classification of lung tumors being one of the chapters. The principles remain those of using morphology first, supported by immunohistochemistry, and then molecular techniques. In 2015, there was particular emphasis on using immunohistochemistry to make classification more accurate. In 2021, there is greater emphasis throughout the book on advances in molecular pathology across all tumor types. Major features within this edition are (1) broader emphasis on genetic testing than in the 2015 WHO Classification; (2) a section entirely dedicated to the classification of small diagnostic samples; (3) continued recommendation to document percentages of histologic patterns in invasive nonmucinous adenocarcinomas, with utilization of these features to apply a formal grading system, and using only invasive size for T-factor size determination in part lepidic nonmucinous lung adenocarcinomas as recommended by the eighth edition TNM classification; (4) recognition of spread through airspaces as a histologic feature with prognostic significance; (5) moving lymphoepithelial carcinoma to squamous cell carcinomas; (6) update on evolving concepts in lung neuroendocrine neoplasm classification; (7) recognition of bronchiolar adenoma/ciliated muconodular papillary tumor as a new entity within the adenoma subgroup; (8) recognition of thoracic SMARCA4-deficient undifferentiated tumor; and (9) inclusion of essential and desirable diagnostic criteria for each tumor. 相似文献
42.
43.
目的研究利用经聚乙烯亚胺(PEI)钝化的荧光碳点(CD)装载阿霉素(DOX)进行药物递送,旨在增加DOX对非小细胞肺癌的治疗作用,减少DOX的心肌毒性。 方法通过一步微波加热法将甘油和PEI的混合物制备成CD-PEI,并通过静电效应将DOX装载至CD-PEI。采用CCK8实验检测CD-PEI-DOX对非小细胞肺癌细胞A549的增殖能力的影响;Transwell实验评估CD-PEI-DOX对A549细胞迁移侵袭能力的影响;最后通过体内动物实验评估CD-PEI-DOX的心肌毒性以及对非小细胞肺癌皮下肿瘤生长的抑制效果。 结果体外细胞实验证实,对比单纯的DOX处理组,CD-PEI-DOX对非小细胞肺癌A549细胞增殖、迁移侵袭能力的抑制作用更为显著。体内实验证实,CD-PEI-DOX纳米复合物治疗组小鼠心肌细胞结构完整,并且能有效抑制小鼠皮下肺癌肿瘤的生长。 结论经PEI钝化的荧光碳点负载阿霉素能显著提高DOX对非小细胞肺癌的治疗效果,并减少DOX对心脏的毒性作用。运用CD-PEI纳米颗粒改善化疗药物递送的治疗方案取得了初步证实,这可为肺癌化学治疗提供新思路,具有广大的临床应用前景。 相似文献
44.
Evaluation of the Role of Merromoside from Ipomoea aquatica Forsskal Hydroalcoholic Extract in the Downregulation of ROS Species in Overcoming MDR in Breast Cancer 下载免费PDF全文
Sasikala MMohan SSwarnakumari SNagarajan A 《Asian Pacific journal of cancer prevention》2022,23(11):3657-3663
Purpose: The medicinal plant Ipomoea aquatica belonging to convulvulaceae family is an effective natural herb for treatment of various ailments and possesses effective anticancer activity. The aim of the work is to characterize a secondary metabolite merromoside (a resin glycoside) for anti-breast cancer activity through down regulation of ROS species. Methods: The Extract of the whole plant has been prepared by maceration method using 50%v/v ethanol in distilled water to get a hydroalcoholic extract. The phytochemical evaluation reveals that the active secondary metabolite was isolated by using column chromatographic technique. The isolated compound was evaluated for its anticancer properties through invitro method such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay on Michigan Cancer Foundation-7 Cell lines. The purity and structural characterization were done by high-performance thin layer chromatography, Fourier Transform Infrared Spectroscopy, Proton and13C Nuclear Magnetic Resonance spectroscopy and Liquid Chromatography–Mass Spectrometry. Results: The isolated compound (W04) from the derived extract showed Rf value of 0.79 that showed IC50 of 182.8μg/ml. The chemical structure of W04 has been confirmed as [4,5-dihydroxy-6-[5-hydroxy-2-methyl-4-(2-methylpropanoyloxy)-6-[(24,25,26-trihydroxy-5,23-dimethyl-9-oxo-19-pentyl-2,4,8,20,22-pentaoxatricyclo[19.2.2.13,7]hexacosan-6-yl)oxy]oxan-3-yl]oxy-2-methyloxan-3-yl] 2-methyl propanoate with the molecular weight of 979.15268. The isolated compound merromoside from hydroalcoholic extract of Ipomoea aquatica has been evaluated for anti-breast cancer properties. The down regulation of ROS species will prevent reverse signalling and angiogenesis. This indicates that merromoside will overcome MDR in breast cancer especially DOX-resistant. 相似文献
45.
46.
47.
《Journal of pediatric surgery》2023,58(9):1613-1617
BackgroundThe goal of this study was to characterize contemporary performance benchmarks and risk factors associated with negative appendectomy (NA) in children with suspected appendicitis.MethodsA multicenter retrospective cohort analysis of children undergoing appendectomy for suspected appendicitis was performed using data from the 2016–2021 NSQIP-Pediatric Appendectomy Targeted Public Use Files. Multivariable regression was used to evaluate the influence of year, age, sex, and WBC count on NA rate, and to generate rate estimates for NA based on different combinations of demographic characteristics and WBC profiles.Results100,322 patients were included from 140 hospitals. The overall NA rate was 2.4%, and rates decreased significantly during the study period (2016: 3.1% vs. 2021: 2.3%, p < 0.001). In adjusted analyses, the highest risk for NA was associated with a normal WBC (<9000/mm3; OR 5.31 [95% CI: 4.87–5.80]), followed by female sex (OR 1.55 [95% CI: 1.42–1.68]) and age <5 years (OR 1.64 [95% CI 1.39, 1.94]). Model-estimated risk for NA varied significantly across demographic and WBC strata, with a 14.4-fold range in rates between subgroups with the lowest and highest predicted risk (males 13–17 years with elevated WBC [1.1%] vs. females 3–4 years with normal WBC [15.8%]).ConclusionsContemporary NA rates have decreased over time, however NA risk remains high in children without a leukocytosis, particularly for girls and children <5 years of age. These data provide contemporary performance benchmarks for NA in children with suspected appendicitis and identify high-risk populations where further efforts to mitigate NA risk should be targeted.Level of EvidenceIII. 相似文献
48.
49.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
50.
目的:研究血清和尿液中外泌体miRNAs的表达水平对肾细胞癌(RCC)的诊断价值。方法:选择本院2018年11月至2020年08月诊治的68例RCC患者(RCC组)进行前瞻性分析,并将RCC患者根据临床分期进行分组,以本院同期收治的60例肾脏良性病变患者作为对照组。检测患者血清和尿液中外泌体miRNAs相对表达量,分析血清和尿液中外泌体miRNAs在肾细胞癌中的诊断价值。结果:RCC组患者血清、尿液中miR-210、miR-21、miR-153、miR-1233和miR-221表达量均明显高于对照组,miR-34a表达量均明显低于对照组(P<0.05);血清中ROC曲线显示AUC最大的为miR-221,其诊断敏感度为79.40%,特异度为95.00%;尿液中最大的为miR-34a,其敏感度为85.30%,特异度为88.30%;不同临床分期RCC患者的血清miR-210、miR-153表达量以及尿液miR-153表达量无显著差异(P>0.05),但血清和尿液中的miR-21、miR-34a、miR-1233、miR-221表达量以及尿液miR-210表达量在不同分期RCC患者中存在显著差异(P<0.05);血清中,miR-210、miR-153与临床分期无相关性(P>0.05),miR-21、miR-1233、miR-221与临床分期呈正相关,miR-34a与临床分期呈负相关(P<0.05);尿液中,miR-210、miR-153与临床分期无相关性(P>0.05),miR-21、miR-1233、miR-221与临床分期呈正相关,miR-34a与临床分期呈负相关(P<0.05)。结论:RCC患者血清、尿液外泌体miR-210、miR-21、miR-34a、miR-153、miR-1233和miR-221表达量较良性肾脏病变患者存在显著差异,同时miR-21、miR-34a、miR-1233、miR-221表达量均与RCC患者病理分期存在显著相关性,可为疾病进展评估提供参考。 相似文献